ArticleCureus2025
Zoledronic Acid Treatment for Diffuse Sclerosing Osteomyelitis of the Mandible: A Case Report and Literature Review of Antiresorptive Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse sclerosing osteomyelitis (DSO) is a rare, chronic aseptic osteomyelitis of the mandible characterized by resistance to conventional therapies including nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, corticosteroids, and surgery. Diagnosis is often delayed due to nonspecific symptoms and lack of typical infectious signs, sometimes resulting in misdiagnosis. We report a case of a 58-year-old male patient with persistent mandibular pain initially misdiagnosed as trigeminal neuralgia and treated with microvascular decompression surgery without improvement. Subsequent imaging revealed bone sclerosis and resorption consistent with DSO. IV administration of zoledronic acid resulted in rapid and sustained pain relief, improved mouth opening, and radiographic bone regeneration without adverse events. A review of 139 reported cases treated with antiresorptive agents (ARAs) including bisphosphonates (BPs) and denosumab (DMB) demonstrated a high remission rate (95%), though treatment protocols varied widely. BPs appear preferable to DMB due to longer duration of effect and lower risk of medication-related osteonecrosis of the jaw (MRONJ). This case and literature review underscore the efficacy and safety of ARAs in managing DSO but highlight the need for standardized treatment guidelines and further prospective studies to optimize therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.